冠狀動脈疾病的抗血小板和抗血栓治療:以證據為基礎的方法和臨床考慮因素
Antiplatelet and antithrombotic therapies represent cornerstone treatments in the management of coronary artery disease, playing crucial roles in preventing thrombotic complications across the spectrum from
Antiplatelet and antithrombotic therapies represent cornerstone treatments in the management of coronary artery disease, playing crucial roles in preventing thrombotic complications across the spectrum from
Coronary artery bypass grafting (CABG) remains the gold standard revascularization strategy for many patients with complex coronary artery disease, despite advances in percutaneous coronary intervention.
Cardiac biomarkers have revolutionized the diagnosis, risk stratification, and management of coronary artery disease, providing objective, quantifiable measures of myocardial injury, stress, and inflammation that
Post-thrombotic syndrome (PTS) represents one of the most common and debilitating long-term complications of deep vein thrombosis (DVT), affecting 20-50% of patients within two years
Catheter-directed thrombolysis (CDT) represents an important advancement in the management of deep vein thrombosis (DVT), offering a minimally invasive approach to actively remove thrombus and
Inferior vena cava (IVC) filters represent an important therapeutic option in the management of venous thromboembolism (VTE), particularly when anticoagulation is contraindicated or has failed.
Cardiopulmonary bypass (CPB) represents one of the most significant technological advances in modern medicine, enabling complex cardiac surgical procedures by temporarily assuming the functions of
Aortic aneurysms represent a significant cardiovascular condition characterized by abnormal dilation of the aorta, the body’s main arterial vessel, carrying oxygenated blood from the heart
Heart valve disease affects millions of people worldwide, often requiring valve replacement when repair is not feasible. The evolution of prosthetic heart valves represents one
The successful repair of an aortic aneurysm—whether through open surgical or endovascular approaches—represents not the end of patient care but rather a transition to a
我們很樂意回答您的任何問題,並協助您決定哪項服務最符合您的需求。
我們會在您方便的時候安排通話
我們會開會討論和諮詢
我們準備一份建議書
若有一般或產品相關問題,請填寫我們的快速線上表格。您將收到確認和參考編號,以便追蹤。
若有一般或產品相關問題,請填寫我們的快速線上表格。您將收到確認和參考編號,以便追蹤。
若有一般或產品相關問題,請填寫我們的快速線上表格。您將收到確認和參考編號,以便追蹤。
若有一般或產品相關問題,請填寫我們的快速線上表格。您將收到確認和參考編號,以便追蹤。
若有一般或產品相關問題,請填寫我們的快速線上表格。您將收到確認和參考編號,以便追蹤。